Welcome to LookChem.com Sign In|Join Free

CAS

  • or

189205-49-0

Post Buying Request

189205-49-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

189205-49-0 Usage

General Description

1-Piperidinecarboxylic acid, 4-(methylsulfonyl)-, 1,1-dimethylethyl ester is a chemical compound that is commonly used in the pharmaceutical industry as an intermediate for the synthesis of various drugs. It is a derivative of piperidinecarboxylic acid and is commonly referred to as Boc-protected piperidine-4-sulfonamide. This chemical is highly reactive and is often used as a reagent in organic synthesis, especially in the production of pharmaceuticals and fine chemicals. It is also used as a building block in the synthesis of biologically active compounds, making it a valuable chemical in the pharmaceutical and chemical industries.

Check Digit Verification of cas no

The CAS Registry Mumber 189205-49-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,9,2,0 and 5 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 189205-49:
(8*1)+(7*8)+(6*9)+(5*2)+(4*0)+(3*5)+(2*4)+(1*9)=160
160 % 10 = 0
So 189205-49-0 is a valid CAS Registry Number.

189205-49-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl 4-methylsulfonylpiperidine-1-carboxylate

1.2 Other means of identification

Product number -
Other names 4-methanesulfonyl-piperidine-carboxylic acid tert-butyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:189205-49-0 SDS

189205-49-0Relevant articles and documents

COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY

-

Paragraph 00218, (2017/04/11)

The present invention relates to compounds characterized by having a structure according to the following Formula (I), or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.

Rational design of phosphoinositide 3-kinase inhibitors that exhibit selectivity over the phosphoinositide 3-kinase isoform

Heffron, Timothy P.,Wei, Binqing,Olivero, Alan,Staben, Steven T.,Tsui, Vickie,Do, Steven,Dotson, Jennafer,Folkes, Adrian J.,Goldsmith, Paul,Goldsmith, Richard,Gunzner, Janet,Lesnick, John,Lewis, Cristina,Mathieu, Simon,Nonomiya, Jim,Shuttleworth, Stephen,Sutherlin, Daniel P.,Wan, Nan Chi,Wang, Shumei,Wiesmann, Christian,Zhu, Bing-Yan

experimental part, p. 7815 - 7833 (2012/01/05)

Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3K has justly received the most attention for its potential in cancer therapy. Herein we report our successful approaches to achieve PI3K vs PI3K selectivity for two chemical series. In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3K that is not attained with the corresponding Lys777 of PI3K. In the benzoxepin series of inhibitors, the selectivity observed can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

-

Page/Page column 56; 57, (2009/11/29)

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119; such as, but not limited to, diabetes, obesity and associated metabolic disorders. Formula (I) is a compound, in which A can have up to 2 ring -CH2- group substituted with -C(O)- and can be partially unsaturated with up to 2 double bonds; Wi and W2 are independently selected from CR10 and N; wherein R10 is selected from hydrogen and C1_6alkyl; Yi is selected from NRn, O and S; wherein Rn is selected from hydrogen and C1_ 6alkyl; Y2 and Y3 are independently selected from CH and N; Y4 is selected from CH2, OCH2 and NR15; wherein R15 is selected from hydrogen and C1_6alkyl; or the pharmaceutically acceptable salts thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 189205-49-0